Granahan Investment Management LLC Acquires 496,482 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Granahan Investment Management LLC boosted its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 43.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,636,381 shares of the company's stock after buying an additional 496,482 shares during the period. Granahan Investment Management LLC owned approximately 0.80% of Taysha Gene Therapies worth $2,831,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TSHA. Ground Swell Capital LLC bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at about $25,000. Cibc World Markets Corp bought a new stake in Taysha Gene Therapies during the fourth quarter valued at approximately $28,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies during the fourth quarter valued at approximately $31,000. Hsbc Holdings PLC grew its stake in Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after buying an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP bought a new position in shares of Taysha Gene Therapies in the 4th quarter worth $39,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Trading Up 0.9%

Shares of NASDAQ:TSHA traded up $0.02 during trading on Tuesday, reaching $2.34. 2,299,548 shares of the company traded hands, compared to its average volume of 2,825,624. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The firm has a market capitalization of $479.83 million, a price-to-earnings ratio of 3.71 and a beta of 0.90. The business's fifty day moving average is $1.67 and its 200-day moving average is $1.81.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.02 million during the quarter, compared to analysts' expectations of $2.05 million. As a group, analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Chardan Capital reiterated a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. JMP Securities reiterated a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.